Corbus Pharmaceuticals Holdings Inc CRBP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit
-
Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference
-
Obesity drugs' next wave: These companies could snag 20% of GLP-1 market, analysts say
-
Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
-
Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
-
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
-
Corbus Pharmaceuticals Reaches 2-Year High After Drug Results
Trading Information
- Previous Close Price
- $21.49
- Day Range
- $20.79–22.20
- 52-Week Range
- $3.03–61.90
- Bid/Ask
- $20.71 / $21.10
- Market Cap
- $251.96 Mil
- Volume/Avg
- 997,463 / 599,818
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 19
- Website
- https://www.corbuspharma.com
Comparables
Valuation
|
Metric
|
CRBP
|
MGNX
|
VRDN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.92 | 3.46 | 4.52 |
Price/Sales | — | 5.03 | 4,424.43 |
Price/Cash Flow | — | — | — |
Price/Earnings
CRBP
MGNX
VRDN
Financial Strength
|
Metric
|
CRBP
|
MGNX
|
VRDN
|
|---|---|---|---|
Quick Ratio | 6.13 | 2.53 | 15.54 |
Current Ratio | 6.18 | 2.71 | 15.82 |
Interest Coverage | −24.10 | −128.87 | −92.88 |
Quick Ratio
CRBP
MGNX
VRDN
Profitability
|
Metric
|
CRBP
|
MGNX
|
VRDN
|
|---|---|---|---|
Return on Assets (Normalized) | −40.26% | −59.21% | −34.35% |
Return on Equity (Normalized) | −68.93% | −120.96% | −64.16% |
Return on Invested Capital (Normalized) | −45.68% | −102.88% | −41.62% |
Return on Assets
CRBP
MGNX
VRDN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Jgnlsmtwk | Wllz | $531.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Fxchqbww | Xwfpnjs | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Pmwmqsj | Fgtnrj | $114.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Khvznqqb | Rmjvspd | $35.3 Bil | |||
| argenx SE ADR
ARGX
| Kypyhlr | Bbxk | $32.0 Bil | |||
| BioNTech SE ADR
BNTX
| Qxssrvp | Rklkj | $28.1 Bil | |||
| Moderna Inc
MRNA
| Vdwnkxytn | Wmxf | $25.3 Bil | |||
| United Therapeutics Corp
UTHR
| Gvgddskgw | Nfbj | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Lmblybwbb | Xfwdfg | $13.4 Bil | |||
| Incyte Corp
INCY
| Vfbtsrpp | Nhsxyfz | $12.7 Bil |
United States